IGOB131 and Tirzepatide
Supplement–drug interaction evidence from the TruthStack database.
| Severity | LOW |
|---|---|
| Evidence Tier | Needs Verification |
| Interaction Type | PHARMACODYNAMIC RISK |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-03-03 |
Source Verification
Attestation METHODOLOGY_ATTESTED
Corpus manifest 26b2d684...
Last reviewed 2026-03-03
Primary source 31855111
Live attestation Query API — returns signed DAA ID per request
Data license CC BY 4.0
Summary
IGOB131 showed reduced glucose AUC in one independent trial. Earlier trials reported dramatic glucose reductions not replicated independently. Clinical significance with tirzepatide uncertain. Discuss with prescriber if experiencing symptoms of low blood sugar.
What We Don't Know
This interaction has needs verification evidence. Key gaps may include: direct clinical trial data for this specific combination, dose-response relationships, and long-term outcome data. Absence of evidence is not evidence of absence.
API Reference
GET https://api.truthstack.co/v1/check?c1=IGOB131&c2=Tirzepatide
Open, unauthenticated. Returns JSON. Developer documentation
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.